Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 22,500 shares, an increase of 8.2% from the May 31st total of 20,800 shares. Based on an average trading volume of 73,900 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $4.00 target price on shares of Alterity Therapeutics in a report on Thursday, March 7th.

Alterity Therapeutics Stock Performance

Shares of NASDAQ ATHE opened at $1.82 on Thursday. The company has a 50 day simple moving average of $1.96 and a 200 day simple moving average of $2.02. Alterity Therapeutics has a 1 year low of $1.55 and a 1 year high of $5.41.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.